IL-ISACA
14.10.2021 16:21:10 CEST | Business Wire | Press release
Reforms following the 2008 financial crisis helped strengthen the resilience of the financial sector, but did not fully address digital operational resilience. The European Union’s recently released Digital Operational Resilience Act (DORA) draft is designed to provide digital operational resilience rules for EU financial institutions, and ISACA provides guidance on this proposal in its new white paper, Digital Operational Resilience in the EU Financial Sector: A Risk-Based Approach .
When finalized, DORA will enact rules for financial services system operators like investment firms, credit institutions, trading venues and electronic money institutions to ensure these systems’ stability and resilience to cyber incidents. Digital Operational Resilience in the EU Financial Sector outlines the objectives and legal basis for DORA, as well as its information and communication technology (ICT) requirements around risk management, information and cybersecurity, incident reporting, testing, and oversight of third-party service providers, some of which include:
- Set up and maintain resilient ICT systems and tools that minimize the impact of ICT risk.
- Have an ICT risk-management framework that includes strategies, policies, procedures, ICT protocols and tools necessary to effectively protect all relevant physical components and infrastructures from risk, such as damage and unauthorized access or usage.
- Test the ICT business continuity policy and the ICT disaster recovery plan at least yearly, and after substantive changes to the ICT systems.
- Include relevant provisions on accessibility, availability, integrity, security and protection of personal data, and guarantees for access, recover and return in the case of failures of the ICT third-party service providers in contracts that govern the relationship with third-party providers.
“The requirements laid out in DORA to identify all sources of ICT risk on a continuous basis and mandate an annual review of ICT risk management frameworks and review after a major incident, audit or testing are a step in the right direction,” says Chris Dimitriadis, ISACA chief global strategy officer. “However, to further strengthen the act, ISACA encourages provisions ensuring that ICT risk management plans go beyond being a compliance exercise by embedding governance responsibility within the management body, as well as requiring continuous training and ICT awareness of senior management and staff and independent testing performed by testers who are certified.”
During this period in which the DORA regulation is under consideration in the European Parliament and Council of the EU, ISACA’s EU Task Force is engaging with policy makers and sharing feedback. The final version of the regulation is expected in an estimated 18-24 months.
“ISACA is recognized among policy makers as an independent source of expertise on cybersecurity issues. The variety of backgrounds and experience of our members, reflected in the EU Task Force, have been welcomed by policy makers who have valued our contributions to the debate,” says Emily Bastedo, ISACA director for global government relations and public affairs.
To download a complimentary copy of Digital Operational Resilience in the EU Financial Sector , visit https://store.isaca.org/s/store#/store/browse/detail/a2S4w000004L1sxEAC . Additional publications that may be helpful for financial entities as they prepare for DORA include ISACA’s Risk IT Framework , 2nd Edition ; Risk IT Practitioner Guide, 2nd Edition ; and IT Risk Fundamentals Study Guide . Other IT risk-related resources can be found at www.isaca.org/resources/it-risk .
About ISACA
For more than 50 years, ISACA® (www.isaca.org ) has advanced the best talent, expertise and learning in technology. ISACA equips individuals with knowledge, credentials, education and community to progress their careers and transform their organizations, and enables enterprises to train and build quality teams. ISACA is a global professional association and learning organization that leverages the expertise of its more than 150,000 members who work in information security, governance, assurance, risk and privacy to drive innovation through technology. It has a presence in 188 countries, including more than 220 chapters worldwide. In 2020, ISACA launched One In Tech, a philanthropic foundation that supports IT education and career pathways for under-resourced, under-represented populations.
Twitter:
www.twitter.com/ISACANews
LinkedIn:
www.linkedin.com/company/isaca
Facebook:
www.facebook.com/ISACAGlobal
Instagram:
www.instagram.com/isacanews
View source version on businesswire.com: https://www.businesswire.com/news/home/20211014005760/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 10:00:00 CET | Press release
The two partners launch “Bianca”, the first large-scale digitalisation initiative in Italy focused on histopathological samples, aimed at training AI algorithms to support pathologists’ diagnostic activities. The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying
OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 10:00:00 CET | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with
New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 10:00:00 CET | Press release
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro
Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 10:00:00 CET | Press release
Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 09:15:00 CET | Press release
This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment OptionsOveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
